SpringWorks [SWTX] vs Vertex [VRTX] Detailed Stock Comparison

SpringWorks Therapeutics, Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: SpringWorks Therapeutics, Inc. wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 15 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric SpringWorks Therapeutics, Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 28.40 N/A
Price-to-Book Ratio 8.44 5.92 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 1.77 10.91 SpringWorks Therapeutics, Inc.
PEG Ratio -21.96 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -12.49 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -115.60% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -164.07% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -51.57% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -28.47% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-196.30M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 27.79% 1.24% SpringWorks Therapeutics, Inc.
Price-to-Sales Ratio (TTM) 16.12 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $3.26B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 14.84 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) 92.81% 85.39% SpringWorks Therapeutics, Inc.
Revenue per Share (TTM) $3 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-3.41 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.70 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 10.18% 1.78% Vertex Pharmaceuticals Inc.

SpringWorks Therapeutics, Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

SWTX
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
SpringWorks Therapeutics, Inc.0.00%0.04%0.69%27.03%27.03%27.03%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
SpringWorks Therapeutics, Inc.27.79%61.20%22.37%107.64%107.64%107.64%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: SpringWorks Therapeutics, Inc. vs Vertex Pharmaceuticals Inc.

MetricSWTXVRTX
Market Information
Market Cap i$3.54B$109.45B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i4,023,9571,057,061
90 Day Avg. Volume i4,304,6921,272,097
Last Close$46.99$428.34
52 Week Range$28.21 - $62.00$362.50 - $507.92
% from 52W High-24.21%-15.67%
All-Time High$96.48 (Feb 08, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-51.30%-17.61%
Growth Metrics
Quarterly Revenue Growth1.34%0.10%
Quarterly Earnings Growth1.34%0.31%
Financial Health
Profit Margin (TTM) i-1.16%0.33%
Operating Margin (TTM) i-1.64%0.40%
Return on Equity (TTM) i-0.52%0.23%
Debt to Equity (MRQ) i1.7710.91
Cash & Liquidity
Book Value per Share (MRQ)$5.57$73.49
Cash per Share (MRQ)$3.82$26.01
Operating Cash Flow (TTM) i$-165,428,000$3.63B
Levered Free Cash Flow (TTM) i$-94,371,752$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: SpringWorks Therapeutics, Inc. vs Vertex Pharmaceuticals Inc.

MetricSWTX (Jul 18, 2025)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A28.40
Forward P/E i-21.9619.95
PEG Ratio i-21.960.88
Price to Sales (TTM) i16.129.22
Price to Book (MRQ) i8.445.92
Market Capitalization
Market Capitalization i$3.54B$109.45B
Enterprise Value i$3.26B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i14.848.83
Enterprise to EBITDA i-12.4921.78
Risk & Other Metrics
Beta i0.700.37
Book Value per Share (MRQ) i$5.57$73.49

Financial Statements Comparison: SpringWorks Therapeutics, Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSWTX (2024)VRTX (2025)
Revenue/Sales i191.59M12.00B
Cost of Goods Sold i12.55M1.65B
COGS % of Revenue i6.6%13.8%
Gross Profit i179.04M10.35B
Gross Margin i93.4%86.2%
Research & Development i200.52M4.04B
Operating Income (EBIT) i-278.13M4.55B
Operating Margin i-145.2%37.9%
EBITDA i-274.66M5.25B
EBITDA Margin i-143.4%43.7%
Pre-Tax Income i-258.13M4.64B
Pre-Tax Income % of Revenue i-134.7%38.7%
Income Tax iN/A690.00M
Income Tax % of Revenue i0.0%5.7%
Net Income (Profit) i-258.13M3.95B
Profit Margin i-134.7%32.9%

Balance Sheet & Liquidity Metrics

MetricSWTX (2024)VRTX (2025)
Cash & Equivalents i69.75M5.08B
Total Current Assets i380.47M11.20B
Total Current Assets % of Revenue i198.6%93.3%
Total Current Liabilities i99.99M3.86B
Total Current Liabilities % of Revenue i52.2%32.2%
Long-Term Debt i6.18M1.95B
Long-Term Debt % of Revenue i3.2%16.3%
Total Shareholders Equity i481.10M18.67B
Retained Earnings i-1.15B13.56B
Retained Earnings % of Revenue i-601.9%113.0%
Property, Plant & Equipment i11.26M1.56B

Cash Flow Statement Comparison

MetricSWTX (2024)VRTX (2025)
Operating Cash Flow i-215.08M3.77B
Operating Cash Flow % of Revenue i-112.3%31.4%
Capital Expenditures iN/A-437.60M
Free Cash Flow i-196.30M3.19B
FCF Margin i-102.5%26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase i-8.44M-2.39B

Short Interest & Institutional Ownership Analysis

MetricSWTXVRTX
Shares Short i6.38M4.02M
Short Ratio i1.462.80
Short % of Float i10.18%1.78%
Shares Outstanding i74.40M253.99M
Float Shares i74.16M253.24M
% Held by Insiders i1.28%0.21%
% Held by Institutions i87.40%97.60%
% Held by Public i11.32%2.19%

Dividend Analysis & Yield Comparison: SpringWorks Therapeutics, Inc. vs Vertex Pharmaceuticals Inc.

MetricSWTXVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A